Aeluma Announces Fourth Quarter and Full Fiscal Year 2026 Financial Results
Aeluma’s losses widened as it ramped investment, while cash, contracts, and CHIPS-related funding prospects strengthened its commercialization plans.
Rhea-AI Summary
Aeluma (ALMU) reported fiscal Q4 and full-year 2026 results and announced growth initiatives, including a CHIPS R&D letter of intent for up to $30 million, on September 16, 2026.
Q4 2026 revenue was $0.6 million versus $1.3 million a year earlier, with a net loss of $4.0 million, or ($0.22) per share, compared with a $0.9 million loss, or ($0.05) per share. Full-year 2026 revenue was $4.5 million versus $4.7 million in 2025, and net loss widened to $9.2 million, or ($0.52) per share, from $3.0 million, or ($0.23) per share. Adjusted EBITDA loss was $5.2 million versus a $0.2 million gain.
The company executed six new contracts totaling $5.3 million, expanded partnerships including a new agreement with Sumitomo Chemical Advanced Technologies, grew headcount to 30+ and increased cash to $56.0 million, including $20.1 million raised via an at-the-market program. Management highlighted a strategic shift toward commercialization in AI datacom.
Positive
- CHIPS LOI for up to $30 million to support AI and advanced computing photonics development and commercialization
- Executed six new contracts totaling $5.3 million, including awards from NASA and the U.S. Navy
- Cash and cash equivalents rose to $56.0 million at June 30, 2026 from $15.7 million a year earlier
- Raised $20.1 million net via issuance of 830,484 shares under an at-the-market offering program
- Stockholders’ equity increased to $56.9 million from $17.9 million, with book value per share at $3.06 versus $1.13
- Expanded manufacturing capacity plans via additional MOCVD tools and a new agreement with Sumitomo Chemical Advanced Technologies
Negative
- Q4 2026 revenue declined to $0.6 million from $1.3 million in Q4 2025
- Full-year net loss increased to $9.2 million from $3.0 million year-over-year
- Adjusted EBITDA moved from a $0.2 million gain to a $5.2 million loss for full-year 2026
- Operating expenses more than doubled to $14.6 million from $6.8 million year-over-year
- Net loss per share widened to ($0.22) in Q4 2026 from ($0.05) in Q4 2025
- Equity financing and ATM issuance added 830,484 new shares, diluting existing shareholders while funding growth
News Explained
Existing holders face completed share-count dilution, while up to $30 million of CHIPS support is not yet committed.
Aeluma reports completed financing of
The company says its signed CHIPS letter of intent covers up to
An at-the-market program allows an issuer to sell new shares gradually at prevailing market prices; in this case, the release describes the
Details
Market Reaction – ALMU
Following this news, ALMU has declined 6.63%, reflecting a notable negative market reaction. Argus tracked a trough of -5.7% from its starting point during tracking. Our momentum scanner has triggered 16 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $12.54. Trading volume is elevated at 2.8x the average, suggesting increased selling activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- CHIPS LOI
- Up to $30 million
- Department of Commerce CHIPS R&D Office; subject to definitive agreements
- New contracts
- $5.3 million
- Six contracts executed during fiscal 2026
- Cash and equivalents
- $56.0 million
- At June 30, 2026
- ATM offering proceeds
- $20.1 million net proceeds; 830,484 shares at $24.87
- Fiscal 2026 original issuance under existing ATM program
- Q4 revenue
- $0.6 million
- Fourth quarter fiscal 2026 versus $1.3 million in Q4 2025
- Q4 net loss
- $4.0 million, or $0.22 per share
- Fourth quarter fiscal 2026 versus $0.9 million loss, or $0.05 per share
- Full-year revenue
- $4.5 million
- Fiscal 2026 versus $4.7 million in fiscal 2025
- Full-year net loss
- $9.2 million, or $0.52 per share
- Fiscal 2026 versus $3.0 million loss, or $0.23 per share
Previous Earnings Reports
-
Revenue declined year over year while net loss and adjusted EBITDA loss increased.
-
Results included a net loss and adjusted EBITDA loss despite reaffirmed revenue guidance.
-
Revenue increased year over year, but the company reported a net loss.
-
Full-year revenue increased, while the company issued forward revenue guidance.
-
Revenue rose sharply and the company reported net income alongside a public offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mocvd technical
non-recurring engineering technical
adjusted ebitda financial
gaap financial
at-the-market offering program financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Signed CHIPS Letter of Intent for up to
Executed New Strategic Agreement With Sumitomo Chemical Advanced Technologies to Expand Relationship and Increase Wafer Capacity
GOLETA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU) (“Aeluma” or the “Company”), a semiconductor company specializing in high-performance, scalable technologies for AI, mobile and consumer, defense and aerospace, and quantum, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2026.
Fiscal 2026 and Subsequent Highlights
- CHIPS LOI: Signed a letter of intent (LOI) for up to
$30 million with the Department of Commerce CHIPS R&D Office for development and commercialization of photonics for AI and Advanced Computing. - Strengthened Relationships with Key Partners: Announced partnerships with Tower Semiconductor and Sumitomo Chemical Advanced Technologies to position Aeluma for qualification and scaling.
- Increased Manufacturing Capabilities: Procuring additional MOCVD tools for increased wafer production capacity for the Company’s non-indium-phosphide (non-InP) platforms.
- Leadership and Team Expansion: Grew team from 14 to more than 30 people, attracting top talent from industry to execute our product development and go-to-market strategy. Added Vice President of Engineering, Senior Director of Program and Project Management, and other key hires across the organization.
- Executed New Contracts: Executed six new contracts totaling
$5.3 million in value, including awards from NASA, the U.S. Navy, and others. Programs accelerate development of Aeluma’s photodetector, laser, and quantum technologies. - Expanded Customer Engagements: Advanced customer discussions to multi-million-dollar non-recurring engineering (NRE) negotiations focused on photonics for AI datacom.
- Bolstered Cash Position for Growth: Added
$20.1 million bringing cash and cash equivalents to$56.0 million at June 30, 2026, to support equipment and capabilities investments, team growth, and other commercialization efforts.
Management Commentary
“The AI Datacom opportunity has grown significantly, with some market analysts projecting the Data Center IT Semiconductors and Components market will surpass
“After establishing a foundation for commercialization in fiscal 2026 that included more than doubling the size of our team, establishing strategic manufacturing partnerships, and bolstering cash, the Company is transitioning from early-stage R&D Government contracts to a focus on scale and commercialization. To this end, we announced a letter of intent (LOI) with the Department of Commerce CHIPS R&D Office for up to
“Fiscal 2027 will focus on technology and product development, and expanding our customer engagements. We are in discussions with several important prospective customers in the AI datacom industry, negotiating NRE agreements that could support our go-to-market strategy. We will continue to grow our team, we are adding MOCVD wafer production capacity, and we executed an important agreement to expand our relationship with supply chain partner Sumitomo Chemical Advanced Technologies. We believe it is timely to make these investments given the projected scale of our market opportunities, and our customers are aligned with our strategy. Finally, the CHIPS R&D funding, which is subject to definitive agreement negotiations, could accelerate our commercialization timeline,” concluded Dr. Klamkin.
Fiscal Q4 2026 Financial Results
- Revenue was
$0.6 million , compared to$1.3 million in the fourth quarter of 2025 and was primarily from R&D contracts. - Net loss was
$4.0 million , or ($0.22) per basic and diluted share, compared to a net loss of$0.9 million , or ($0.05) per basic and diluted share, for the same period last year. - Adjusted EBITDA loss was
$2.9 million , compared to a loss of$0.1 million in the same period last year. - Cash and cash equivalents totaled
$56.0 million at June 30, 2026, compared to$37.8 million in the prior quarter. - Aeluma raised
$20.1 million in net proceeds from the original issuance of 830,484 shares at an average price of$24.87 under its existing at-the-market offering program.
Full Year 2026 Financial Results
- Full year revenue was
$4.5 million , compared to$4.7 million in the prior year, and was primarily from government R&D contracts. - Net loss was
$9.2 million , or ($0.52) per basic and diluted share, compared to a net loss of$3.0 million , or ($0.23) per basic and diluted share, for the prior year. - Adjusted EBITDA loss was
$5.2 million , compared to a gain of$0.2 million in the prior year. - Net loss and adjusted negative EBITDA increased year-over-year, primarily reflecting investments in strategic new hires and manufacturing readiness.
Conference Call and Webcast
Aeluma will host a conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on September 16, 2026, to discuss the Company’s financial results and business outlook. Interested participants may access the conference call by dialing (877) 317-6789 (domestic) or (412) 317-6789 (international) and referencing “Aeluma.”
A live webcast of the call will be available on the “Investors” section of Aeluma’s website and can also be accessed by clicking here. A replay of the conference call will be available on Aeluma’s website shortly after the call concludes.
Annual Meeting of Stockholders
Aeluma today announced that its board of directors has established November 19, 2026 as the date of its next annual meeting of stockholders (the “Annual Meeting”). The exact time and virtual attendance details for the Annual Meeting will be specified in a definitive proxy statement, which will be filed with the Securities and Exchange Commission.
The date of the Annual Meeting is more than 30 days before the anniversary of Aeluma’s prior annual meeting of stockholders. Accordingly, stockholders who, in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), desire to present proposals (other than director nominations) for inclusion in Aeluma’s proxy materials relating to the Annual Meeting must follow the procedures provided in Rule 14a-8 and our bylaws. To be timely, such proposals must be delivered to or mailed and received by our corporate secretary on or before the close of business on September 26, 2026, which is a reasonable time before printing and mailing of our proxy materials for the meeting.
Stockholders who intend to propose an item of business for consideration at the Annual Meeting, but not have it included in Aeluma’s proxy statement, or intending to nominate a person for election as a director at the Annual Meeting, must provide timely written notice of such proposal or nomination. To be timely under our bylaws, such notice also must be delivered to or mailed and received by our corporate secretary no later than the close of business on September 26, 2026, and must contain the information specified in our bylaws.
In addition to satisfying the foregoing requirements under our bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the nominees selected by our board of directors also must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act, no later than September 26, 2026.
Non-GAAP Financial Measures
This press release includes the following non-GAAP financial measures:
- Non-GAAP net income (loss), which is defined as net income (loss) plus stock-based compensation expenses, amortization of discount on convertible notes, and changes in fair value of derivative liabilities; and
- Adjusted EBITDA, defined as non-GAAP net income (loss) plus depreciation and amortization expenses, less interest income.
The presentation of these financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). We believe that the presentation of these non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to Aeluma’s financial condition and results of operations. We believe that these non-GAAP financial measures provide additional insight into Aeluma’s ongoing performance and core operational activities and provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Aeluma’s results of operations in conjunction with the corresponding GAAP measures.
A reconciliation of each non-GAAP financial measure to its most directly comparable financial measure calculated and presented in accordance with GAAP is provided in the financial statements portion of this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other securities laws. All statements in this press release that are not historical are forward-looking statements, including, among other things, potential applications and resulting benefits of Aeluma’s technology, timing of development and commercialization of Aeluma’s products, anticipated demand and markets for Aeluma’s products, whether Aeluma or the U.S. Department of Commerce will enter into definitive award documents on acceptable terms, or at all, whether Aeluma will receive or retain any portion of the proposed CHIPS funding, and the potential issuance of Company securities to the U.S. Department of Commerce. These statements are not historical facts but rather are based on Aeluma’s current expectations, estimates, and projections regarding its business, operations, and other similar or related factors. Words such as “anticipate,” “could,” “growing,” “intend,” “may,” “plan,” “poised,” “potential,” “will,” “would,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Aeluma’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including Aeluma’s history of losses and limited operating history, and its ability to achieve or sustain profitability; competitive, technological, and market risks affecting the adoption of Aeluma’s semiconductor and photonics products for AI, high-performance computing, and other target markets; general economic, geopolitical, and supply-chain conditions affecting the semiconductor industry; uncertainty as to whether Aeluma and the U.S. Department of Commerce will establish and execute definitive award documents for the proposed funding on acceptable terms, or at all; uncertainty as to whether, when, and in what amount Aeluma will receive or retain any portion of the proposed funding; the perceived and actual dilutive effects of the proposed issuance of common stock; impacts of an equity stake by the U.S. government in Aeluma, including any related reputational, regulatory, or governance considerations; Aeluma’s ability to satisfy applicable milestones associated with the funding; the risk that anticipated benefits of the proposed funding, including acceleration of commercialization and scaling of Aeluma’s non-InP photonics platform, may not be realized on the timeline anticipated or at all; changes in U.S. government policy, funding priorities, or budgetary constraints that could affect the availability or continuation of CHIPS programs; and other risks described in Aeluma’s filings with the U.S. Securities and Exchange Commission. Aeluma undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available, except as required by law.
About Aeluma, Inc.
Aeluma (Nasdaq: ALMU) is a transformative semiconductor company specializing in high-performance photonic and electronic technologies that scale. The company’s proprietary platform combines compound semiconductors with scalable manufacturing used for mass market microelectronics to enable volume production and large-scale integration. Applications for Aeluma’s technology include mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum. Headquartered in Goleta, California, Aeluma operates state-of-the-art R&D and manufacturing capabilities for semiconductor wafer production, quick-turn chip fabrication, rapid prototyping, test and validation. Aeluma also partners with production-scale fabrication foundries, packaging, and integration companies. For more information, visit www.aeluma.com.
Company:
Aeluma, Inc.
(805) 351-2707
info@aeluma.com
Investor Contact:
Financial Profiles, Inc.
Moira Conlon and Donni Case
(310) 622-8224
ir@aeluma.com
| Aeluma, Inc. and Subsidiary Condensed Consolidated Balance Sheets | ||||||||
| ($ in thousands) | June 30, 2026 | June 30, 2025 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 56,006 | $ | 3,628 | ||||
| Certificate of deposit | – | 12,112 | ||||||
| Accounts receivable | 340 | 962 | ||||||
| Prepaids and other current assets | 965 | 633 | ||||||
| Total current assets | 57,311 | 17,335 | ||||||
| Property and equipment: | ||||||||
| Equipment | 2,338 | 1,692 | ||||||
| Leasehold improvements | 547 | 547 | ||||||
| Accumulated depreciation | (1,469 | ) | (1,021 | ) | ||||
| Property and equipment, net | 1,416 | 1,218 | ||||||
| Right of use asset – operating | 1,916 | 836 | ||||||
| Other assets | 21 | 17 | ||||||
| Total assets | $ | 60,664 | $ | 19,406 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 341 | $ | 361 | ||||
| Accrued expenses and other current liabilities | 1,369 | 206 | ||||||
| Lease liability – operating, current portion | 180 | 138 | ||||||
| Total current liabilities | 1,890 | 705 | ||||||
| Lease liability – operating, long-term portion | 1,842 | 803 | ||||||
| Total liabilities | 3,732 | 1,508 | ||||||
| Commitments and contingencies | – | – | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | – | – | ||||||
| Common stock | 2 | 2 | ||||||
| Additional paid-in capital | 82,735 | 34,542 | ||||||
| Accumulated deficit | (25,805 | ) | (16,646 | ) | ||||
| Total stockholders’ equity | 56,932 | 17,898 | ||||||
| Total liabilities and stockholders’ equity | $ | 60,664 | $ | 19,406 | ||||
| Aeluma, Inc. and Subsidiary Condensed Consolidated Statements of Operations | ||||||||||||||||||||
| Three Months Ended (unaudited) | Twelve Months Ended | |||||||||||||||||||
| ($ in thousands, except per share data) | June 30, 2026 | March 31, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||||||
| Revenue | $ | 582 | $ | 1,222 | $ | 1,317 | $ | 4,461 | $ | 4,665 | ||||||||||
| Operating expenses: | ||||||||||||||||||||
| Cost of revenue | 433 | 836 | 779 | 2,889 | 1,884 | |||||||||||||||
| Research and development | 2,274 | 882 | 165 | 4,668 | 1,295 | |||||||||||||||
| General and administrative | 2,247 | 1,629 | 1,342 | 7,090 | 3,628 | |||||||||||||||
| Total operating expenses | 4,954 | 3,347 | 2,286 | 14,647 | 6,807 | |||||||||||||||
| Loss from operations | (4,372 | ) | (2,125 | ) | (969 | ) | (10,186 | ) | (2,142 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||||||
| Interest income | 359 | 325 | 110 | 1,027 | 113 | |||||||||||||||
| Amortization of discount on convertible notes | – | – | – | – | (715 | ) | ||||||||||||||
| Changes in fair value of derivative liabilities | – | – | – | – | (278 | ) | ||||||||||||||
| Total other income (expense), net | 359 | 325 | 110 | 1,027 | (880 | ) | ||||||||||||||
| Loss before income tax expense | (4,013 | ) | (1,800 | ) | (859 | ) | (9,159 | ) | (3,022 | ) | ||||||||||
| Income tax expense | – | – | – | – | – | |||||||||||||||
| Net loss | $ | (4,013 | ) | $ | (1,800 | ) | $ | (859 | ) | $ | (9,159 | ) | $ | (3,022 | ) | |||||
| Net loss per share – basic and diluted | $ | (0.22 | ) | $ | (0.10 | ) | $ | (0.05 | ) | $ | (0.52 | ) | $ | (0.23 | ) | |||||
| Weighted average common shares outstanding – basic and diluted | 18,603,331 | 18,061,402 | 15,824,222 | 17,665,755 | 13,168,345 | |||||||||||||||
| Book value per share | $ | 3.06 | $ | 2.22 | $ | 1.13 | $ | 3.06 | $ | 1.13 | ||||||||||
| Aeluma, Inc. and Subsidiary Condensed Consolidated Statements of Cash Flows | ||||||||
| Twelve Months Ended June 30, | ||||||||
| ($ in thousands) | 2026 | 2025 | ||||||
| Operating activities: | ||||||||
| Net loss | $ | (9,159 | ) | $ | (3,022 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Amortization of deferred compensation | – | 20 | ||||||
| Stock-based compensation expense | 4,519 | 1,893 | ||||||
| Depreciation and amortization expense | 451 | 415 | ||||||
| Amortization of discount on convertible notes | – | 715 | ||||||
| Changes in fair value of derivative liabilities | – | 278 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 622 | (902 | ) | |||||
| Prepaids and other current assets | (332 | ) | (611 | ) | ||||
| Other assets | (7 | ) | – | |||||
| Accounts payable | (20 | ) | 44 | |||||
| Accrued expenses and other current liabilities | 660 | 22 | ||||||
| Net cash used in operating activities | (3,266 | ) | (1,148 | ) | ||||
| Investing activities: | ||||||||
| Purchase of equipment | (646 | ) | (161 | ) | ||||
| Net cash used in investing activities | (646 | ) | (161 | ) | ||||
| Financing activities: | ||||||||
| Proceeds from stock option exercise | 104 | 25 | ||||||
| Proceeds from stock warrant exercise | 708 | – | ||||||
| Proceeds from convertible notes issuance | – | 3,145 | ||||||
| Proceeds from public offering, net of offering costs | 43,478 | 12,588 | ||||||
| Payment for taxes related to net share settlement of stock options and restricted stock units | (112 | ) | – | |||||
| Net cash provided by financing activities | 44,178 | 15,758 | ||||||
| Net change in cash and cash equivalents, and certificate of deposit | 40,266 | 14,449 | ||||||
| Cash and cash equivalents, and certificate of deposit, beginning of period | 15,740 | 1,291 | ||||||
| Cash and cash equivalents, and certificate of deposit, end of period | $ | 56,006 | $ | 15,740 | ||||
| Supplemental non-cash disclosures: | ||||||||
| Right of use asset – operating obtained in exchange for lease liability – operating | $ | 1,014 | $ | – | ||||
| Conversion of convertible notes to stockholders’ equity | $ | – | $ | 1,667 | ||||
| Conversion of derivative liabilities to stockholders’ equity | $ | – | $ | 2,471 | ||||
| Aeluma, Inc. and Subsidiary Reconciliation of GAAP and Non-GAAP Financial Measures (unaudited) | ||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||||||
| ($ in thousands, except per share data) | June 30, 2026 | March 31, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||||||
| GAAP net loss | $ | (4,013 | ) | $ | (1,800 | ) | $ | (859 | ) | $ | (9,159 | ) | $ | (3,022 | ) | |||||
| Non-GAAP adjustments: | ||||||||||||||||||||
| Stock-based compensation | 1,308 | 1,099 | 744 | 4,519 | 1,893 | |||||||||||||||
| Consulting and advisory | – | – | 3 | – | 20 | |||||||||||||||
| Amortization of discount on convertible notes | – | – | – | – | 715 | |||||||||||||||
| Changes in fair value of derivative liabilities | – | – | – | – | 278 | |||||||||||||||
| Total adjustments to GAAP net loss | 1,308 | 1,099 | 747 | 4,519 | 2,906 | |||||||||||||||
| Non-GAAP net loss | $ | (2,705 | ) | $ | (701 | ) | $ | (112 | ) | $ | (4,640 | ) | $ | (116 | ) | |||||
| Depreciation & amortization | 126 | 115 | 109 | 451 | 415 | |||||||||||||||
| Interest income | (359 | ) | (325 | ) | (110 | ) | (1,027 | ) | (113 | ) | ||||||||||
| Adjusted EBITDA | $ | (2,938 | ) | $ | (911 | ) | $ | (113 | ) | $ | (5,216 | ) | $ | 186 | ||||||
| GAAP net loss per share – basic and diluted | $ | (0.22 | ) | $ | (0.10 | ) | $ | (0.05 | ) | $ | (0.52 | ) | $ | (0.23 | ) | |||||
| Non-GAAP adjustments | 0.07 | 0.06 | 0.04 | 0.26 | 0.22 | |||||||||||||||
| Non-GAAP net loss per share – basic and diluted | $ | (0.15 | ) | $ | (0.04 | ) | $ | (0.01 | ) | $ | (0.26 | ) | $ | (0.01 | ) | |||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.